Clinical Trial Corner

A new study to evaluate the accuracy of a blood test for detecting lung cancer in high-risk adults has enrolled its first participant with plans to enroll thousands more.

Enrollment has begun for a trial evaluating a vaccine as first-line maintenance treatment for metastatic, microsatellite-stable colorectal cancer.

A phase 3 trial has begun to examine entospletinib, a selective inhibitor, as a treatment for patients with newly diagnosed NPM1-mutated acute myeloid leukemia.

A phase 2 trial was recently launched to examine the safety and efficacy of oral inhibitor VK-2019 in patients with advanced Epstein-Barr Virus-positive nasopharyngeal carcinoma, a rare type of head and neck cancer, and lymphoma.

The phase 3 COMPOSE trial will look at the efficacy of using 177lu-edotreotide — a novel radiopharmaceutical that is designed to limit radiation exposure to normal tissue — in patients with later stage neuroendocrine tumors.

There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.

City of Hope has opened its first-in-human clinical trial for an investigational therapy in patients with advanced breast cancer.

Investigators plan to analyze the safety and efficacy of a novel cancer therapy for the treatment of patients with RAF-altered solid tumors.

The first patient was randomized in the phase 2 trial examining Tedopi and Opdivo for non-small cell lung cancer.

A phase 2 trial of aspacytarabine (BST-236) was initiated in patients with AML and MDS.

The TRANSCEND CLL 004 trial is currently enrolling patients to determine the efficacy of a CAR-T cell therapy.

The first patient with bladder cancer was dosed in a phase 1/2 trial examining responses to an investigational immunotherapy.

The first patient has been enrolled in the APOLLO 613 Phase 1/2 clinical trial for CPI-613.

A phase 1 trial of ONO-4685 was initiated for the evaluation of the antibody in patients with relapsed or refractory t-cell lymphoma.

The Food and Drug Administration gave clearance to Bold Therapeutics for a phase 1b/2a trial examining treatments for advanced GI cancers.

The first patients were dosed in a phase 2 trial for a topical gel to treat lesions in patients with colorectal cancer receiving EGFR inhibitor therapy.

Cleveland Clinic’s Lerner Research Institute has initiated a new study to examine a vaccine to prevent triple-negative breast cancer.

A phase 1b trial started to study the effects of fosciclopirox in patients with newly diagnosed and recurrent bladder cancer.

Celsion GmbH has initiated a phase 1 trial to analyze ThermoDox with focused ultrasound for patients with pancreatic cancer.

A company focused on treating underserved patients announced that the first patient with an NTRK fusion was dosed in a phase 2 trial of taletrectinib this summer.

The first patient was enrolled and dosed in InflaRx’s phase 2 trial of vilobelimab for the treatment of cutaneous squamous cell carcinoma.

The PRESERVE 3 trial began this summer to determine efficacy of using Cosela with platinum-based chemotherapy in patients with metastatic bladder cancer.

The first patient was enrolled in a phase 2 clinical trial for the treatment of hormone-sensitive advanced prostate cancer.

Aileron Therapeutics, Inc. announced the initiation of a clinical trial for ALRN-6924, a treatment for patients with non-small cell lung cancer.

A phase 3 clinical trial has begun to evaluate the efficacy and safety of milademetan in patients with de-differentiated liposarcoma.

The first patient was treated in the phase 2b KICKSTART trial testing the safety and efficacy of tomivosertib in combination with Keytruda.

Sierra Oncology completed enrollment for its phase 3 MOMENTUM clinical trial for the treatment of patients with myelofibrosis.

Patients with Bacillus Calmette Guérin-unresponsive carcinoma in-situ will be treated at the University of Chicago in a Theralase study.